Table 2.
Immunophenotypes of WHOest, WHOnew, and ICCnew
| MP-WHOest n = 551∗ |
MD-WHOest n = 654∗ |
WHOnew n = 356∗ |
q value† MD-WHOest vs WHOnew | ICCnew n = 241∗ |
q value† MD-WHOest vs ICCnew | |
|---|---|---|---|---|---|---|
| Aberrant marker expression | 6.0 ± 2.4; 6.0 (0.0-13.0) | 5.2 ± 2.1; 5.0 (0.0-13.0) | 3.9 ± 2.3; 4.0 (0.0-11.0) | <0.001 | 4.4 ± 2.3; 4.0 (0.0-11.0) | 0.003 |
| ≥3 aberrantly expressed surface markers (ICC22 flow criterium) | 318/366 (87%) | 442/484 (91%) | 210/296 (71%) | <0.001 | 152/199 (76%) | <0.001 |
| Blast (%) | 1.4 ± 2.1; 0.6 (0.0-14.0) | 1.3 ± 2.1; 0.7 (0.0-13.0) | 1.3 ± 2.1; 0.7 (0.0-18.0) | >0.9 | 1.5 ± 2.4; 0.8 (0.0-18.0) | 0.2 |
| Granulocytes (%) | 66.8 ± 14.3; 69.0 (20.0-92.0) | 62.9 ± 14.2; 66.0 (13.0-89.0) | 61.6 ± 15.7; 64.0 (11.0-88.0) | 0.7 | 62.3 ± 15.4; 65.0 (11.0-88.0) | >0.9 |
| Monocytes (%) | 12.9 ± 9.5; 11.0 (0.0-56.0) | 10.7 ± 6.0; 10.0 (0.5-37.0) | 5.9 ± 4.1; 5.0 (0.3-22.0) | <0.001 | 5.9 ± 4.0; 4.0 (0.7-20.0) | <0.001 |
| Erythrocytes (%) | 0.9 ± 1.5; 0.4 (0.0-16.0) | 1.3 ± 2.0; 0.6 (0.0-15.0) | 2.0 ± 2.9; 1.0 (0.0-20.0) | 0.002 | 2.2 ± 3.1; 1.0 (0.0-20.0) | 0.002 |
| Monocyte CD2 | 103/209 (49%) | 139/325 (43%) | 49/194 (25%) | <0.001 | 36/129 (28%) | 0.013 |
| Monocyte CD11b | 27/209 (13%) | 37/325 (11%) | 9/194 (4.6%) | 0.021 | 7/129 (5.4%) | 0.15 |
| Monocyte CD13 | 112/209 (54%) | 165/325 (51%) | 65/194 (34%) | <0.001 | 53/129 (41%) | 0.2 |
| Monocyte CD14 | 61/209 (29%) | 86/325 (26%) | 32/194 (16%) | 0.021 | 27/129 (21%) | 0.4 |
| Monocyte CD33 | 28/209 (13%) | 26/325 (8.0%) | 15/194 (7.7%) | >0.9 | 10/129 (7.8%) | >0.9 |
| Monocyte CD45 | 85/209 (41%) | 95/325 (29%) | 21/194 (11%) | <0.001 | 15/129 (12%) | <0.001 |
| Monocyte CD56 | 133/209 (64%) | 179/325 (55%) | 66/194 (34%) | <0.001 | 46/129 (36%) | 0.001 |
| Monocyte HLA-DR | 96/209 (46%) | 125/325 (38%) | 50/194 (26%) | 0.010 | 37/129 (29%) | 0.15 |
| Granulocyte CD13 | 2/209 (1.0%) | 0/325 (0%) | 0/194 (0%) | 0/129 (0%) | ||
| Granulocyte CD33 | 3/209 (1.4%) | 0/325 (0%) | 1/194 (0.5%) | 0.6 | 1/129 (0.8%) | 0.4 |
| Granulocyte CD56 | 29/209 (14%) | 31/325 (9.5%) | 15/194 (7.7%) | 0.7 | 12/129 (9.3%) | >0.9 |
| Granulocyte CD11b-CD16 | 148/209 (71%) | 238/325 (73%) | 124/194 (64%) | 0.053 | 87/129 (67%) | 0.4 |
| Granulocyte CD13-CD16 | 66/209 (32%) | 88/325 (27%) | 49/194 (25%) | 0.8 | 37/129 (29%) | 0.9 |
| Granulocyte CD11b-CD13 | 45/209 (22%) | 40/325 (12%) | 25/194 (13%) | >0.9 | 23/129 (18%) | 0.2 |
| Granulocyte SSC | 0.068 | 0.9 | ||||
| 0 | 92/209 (44%) | 162/325 (50%) | 118/194 (61%) | 70/129 (54%) | ||
| 1 | 89/209 (43%) | 129/325 (40%) | 64/194 (33%) | 47/129 (36%) | ||
| 2 | 28/209 (13%) | 34/325 (10%) | 12/194 (6.2%) | 12/129 (9.3%) | ||
| Erythrocyte CD71 | 44/209 (21%) | 103/325 (32%) | 88/194 (45%) | 0.006 | 61/129 (47%) | 0.008 |
| Blast CD2 | 2/209 (1.0%) | 0/325 (0%) | 1/194 (0.5%) | 0.6 | 1/129 (0.8%) | 0.4 |
| Blast CD5 | 62/209 (30%) | 51/325 (16%) | 16/194 (8.2%) | 0.032 | 12/129 (9.3%) | 0.2 |
| Blast CD7 | 35/209 (17%) | 29/325 (8.9%) | 18/194 (9.3%) | >0.9 | 16/129 (12%) | 0.4 |
| Blast CD11b | 1/209 (0.5%) | 1/325 (0.3%) | 0/194 (0%) | >0.9 | 0/129 (0%) | >0.9 |
| Blast CD13 | 1/209 (0.5%) | 0/325 (0%) | 2/194 (1.0%) | 0.2 | 1/129 (0.8%) | 0.4 |
| Blast CD33 | 1/209 (0.5%) | 0/325 (0%) | 0/194 (0%) | 0/129 (0%) | ||
| Blast CD34 | 1/209 (0.5%) | 3/325 (0.9%) | 1/194 (0.5%) | >0.9 | 1/129 (0.8%) | >0.9 |
| Blast CD34 strong | 0/209 (0%) | 0/325 (0%) | 0/194 (0%) | 0/129 (0%) | ||
| Blast CD45 | 15/209 (7.2%) | 24/325 (7.4%) | 7/194 (3.6%) | 0.14 | 4/129 (3.1%) | 0.2 |
| Blast CD56 | 14/209 (6.7%) | 21/325 (6.5%) | 2/194 (1.0%) | 0.010 | 2/129 (1.6%) | 0.11 |
| Blast CD117 | 0/209 (0%) | 1/325 (0.3%) | 3/194 (1.5%) | 0.2 | 1/129 (0.8%) | 0.6 |
| Blast HLA-DR | 1/209 (0.5%) | 1/325 (0.3%) | 1/194 (0.5%) | >0.9 | 1/129 (0.8%) | 0.6 |
| Blast HLA-DR strong | 1/209 (0.5%) | 0/325 (0%) | 0/194 (0%) | 0/129 (0%) |
∗
Mean ± standard deviation; median (range); n / N (%).
†
Wilcoxon rank sum test; Pearson χ2 test after false discovery rate correction for multiple testing.